Key points
- Point72 Asset Management, its general partner, and Steve Cohen personally disclosed a new 5.7% stake, about 465,000 shares, in Perceptive Capital Solutions Corp (PCSC) in a Schedule 13G filed July 8.
- PCSC is the SPAC taking cancer-detection company Freenome public. Freenome has raised more than $1.3 billion privately since 2014 to build an AI-driven blood test for early cancer detection.
- PCSC's shareholder vote to approve the merger, originally set for July 9, was pushed back to July 15 so the companies could add supplemental disclosures.
- PCSC shares trade around $11, above the roughly $10 a share most SPACs hold in trust, a sign the market expects the deal to close and Freenome to be worth more than the cash-out option.
Point72 Asset Management, Steve Cohen's hedge fund, just disclosed a stake in a company almost nobody's heard of: Perceptive Capital Solutions Corp, a Nasdaq-listed SPAC. I went looking for why, and found something more interesting than the filing itself. The SPAC is taking a cancer-detection startup called Freenome public, and one day after Point72's filing landed, the vote to actually close that deal got pushed back a week.
What Point72 disclosed
In a Schedule 13G filed July 8, 2026, Point72 Asset Management, L.P. reported a 5.7% stake in Perceptive Capital Solutions Corp (PCSC), a Cayman Islands-incorporated SPAC trading on Nasdaq. The stake works out to 465,000 Class A ordinary shares, held as of July 7. Point72 Capital Advisors, Inc., the fund's general partner, and Steven A. Cohen, who controls both entities, are named as joint filers on the same shares.
| Reporting person | Role | Shares | % of class |
|---|---|---|---|
| Point72 Asset Management, L.P. | Investment manager | 465,000 | 5.7% |
| Point72 Capital Advisors, Inc. | General partner | 465,000 | 5.7% |
| Steven A. Cohen | Controls both entities | 465,000 | 5.7% |
All three rows show the same 465,000 shares because they're the same block of stock, not three separate stakes. Point72 Capital Advisors is the general partner of Point72 Asset Management, and Cohen controls both entities, so SEC rules count each of them as a beneficial owner of that one position.
A Schedule 13G is the low-key version of a 5% ownership disclosure: Point72 is certifying that it just owns the shares, not that it's trying to influence how Freenome gets run. That's different from a 13F, the quarterly holdings report funds like Point72 also have to file. I've written before about how the two compare, if you want the full breakdown.
What Freenome actually does
Perceptive Capital Solutions Corp is a blank-check SPAC, basically a shell company that raises money first and goes looking for something to buy second. It IPO'd in 2024 with no underlying business, built specifically to merge with a private company and take it public. The company on the other side of that merger is Freenome, founded in 2014 to build a blood test that screens for cancer before symptoms show up.
Freenome's pitch is a multiomics platform. It reads several different biological signals out of a single blood draw, then runs them through artificial intelligence and machine learning models trained to spot the patterns cancer leaves behind. The company has raised more than $1.3 billion in private funding to build it, backed over the years by investors including SoftBank's Vision Fund, GV, and Kaiser Permanente. It's aiming to launch its first commercial tests, starting with colorectal cancer screening, sometime in 2026.
"Freenome is entering the public markets at an inflection point for our company and for blood-based cancer screening," said Aaron Elliott, Freenome's CEO, when the merger was announced.
Why the vote got delayed
The Business Combination Agreement between Freenome and PCSC was signed December 5, 2025. PCSC filed its definitive proxy statement on June 17, and scheduled the shareholder vote needed to close the deal, an Extraordinary General Meeting, for July 9. On July 9 itself, PCSC announced it was postponing that meeting to July 15, to give itself time to add supplemental disclosures covering events since the proxy was first mailed out. The deadline for shareholders to redeem their PCSC shares for cash instead of staying in the deal was pushed back with it, from its original date to July 13.
The actual proposals shareholders are voting on stayed the same, and any proxies already submitted still count for the rescheduled meeting. This kind of delay is routine in SPAC mergers still working through disclosure requests before a vote. Original guidance when the merger was announced called for closing in the first half of 2026, so a mid-July vote already runs a few weeks behind that.
What the stock is doing
PCSC shares traded around $11.10 as of midday July 9, down from Wednesday's close of $11.36. Most SPACs go public around $10 a share and hold close to that amount in a trust account until a deal closes or the SPAC liquidates. PCSC trading above that level suggests the market thinks Freenome will be worth more, once public, than what a shareholder could get by redeeming now. That's part of why a delay like this doesn't necessarily spook the stock.
The deal itself is structured to bring in about $330 million if few shareholders redeem. That's split between PCSC's trust account and a $240 million private placement led by Perceptive Advisors and RA Capital. Bain Capital Life Sciences, Farallon Capital Management, and ADAR1 Capital are also participating. Together they value the combined company at roughly $1.1 billion. Once the merger closes, PCSC is expected to be renamed Freenome, Inc. and trade on Nasdaq under the ticker FRNM.
What this filing doesn't tell you
A 13G shows what Point72 owned as of a specific date and nothing about why. It doesn't say whether the fund plans to hold through the merger or add to the position. It could just as easily be selling out before the vote even happens. Filing a 13G isn't evidence Point72 has any inside track on Freenome's business or how the vote will go, only that the fund owned the shares as of a certain date. Point72 manages many billions of dollars across thousands of positions; a 465,000-share stake in an $11 stock is a small one by the fund's own standards, whatever the reason behind it.
Point72 joins the growing list of well-known managers whose SEC filings AIStockWire's fund tracker follows. For more on how SPAC mergers work in practice, our deep dive into the CCXI-Agility Robotics humanoid SPAC walks through the mechanics on a different deal.
Sources
- Point72 Schedule 13G, filed July 8, 2026
- Perceptive Capital Solutions Corp 8-K, announcing the vote postponement, July 9, 2026
- Freenome and Perceptive Capital Solutions Corp, business combination announcement
- Our Point72 fund tracker, updated as new filings land
- Related coverage: What is a 13F filing? How to track what hedge funds are buying
- Related coverage: CCXI and Agility Robotics: a deep dive into the humanoid SPAC on Serenity's radar
- Price data via Robinhood market data
- Cover photo: laboratory blood sample processing, U.S. Air Force photo by Staff Sgt. Luis Loza Gutierrez, public domain, via Wikimedia Commons, cropped
This reflects a public SEC filing and price data, not investment advice. Jennifer Song does not hold positions in the securities discussed. Prices are as of midday July 9, 2026 and will move. Always do your own research and consider speaking with a licensed financial professional before making any investment decision.
